Receptor for Advanced Glycation End Products Is Subjected to Protein Ectodomain Shedding by Metalloproteinases*
暂无分享,去创建一个
E. Kojro | F. Fahrenholz | Ling Zhang | Monika Bukulin | A. Roth | Verena V. Metz | P. Nawroth | A. Bierhaus | R. Postina | Annette Roth
[1] P. Saftig,et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane‐bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10) , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[2] C. Heizmann,et al. Calcium-regulated intramembrane proteolysis of the RAGE receptor. , 2008, Biochemical and biophysical research communications.
[3] A. Carter,et al. Identification, classification, and expression of RAGE gene splice variants , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[4] D. Hartmann,et al. Part-Time α-Secretases: The Functional Biology of ADAM 9, 10 and 17 , 2008 .
[5] N. Kaminski,et al. A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. , 2008, The American journal of pathology.
[6] P. Nawroth,et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. , 2007, Cardiovascular diabetology.
[7] D. Stern,et al. RAGE in inflammation: a new therapeutic target? , 2006, Current opinion in investigational drugs.
[8] K. Tsuneyama,et al. Identification of mouse orthologue of endogenous secretory receptor for advanced glycation end-products: structure, function and expression. , 2006, The Biochemical journal.
[9] A. Schmidt,et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. , 2006, Atherosclerosis.
[10] E. Kojro,et al. The neuropeptide PACAP promotes ?‐secretase pathway for processing Alzheimer amyloid precursor protein , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[11] A. D'Angelo,et al. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. , 2005, Archives of neurology.
[12] A. D'Angelo,et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension , 2005, Journal of hypertension.
[13] D. Stern,et al. Understanding RAGE, the receptor for advanced glycation end products , 2005, Journal of Molecular Medicine.
[14] M. Pelto-huikko,et al. Shedding light on ADAM metalloproteinases. , 2005, Trends in biochemical sciences.
[15] N. Ozaki,et al. RasGRP3 mediates phorbol ester-induced, protein kinase C-independent exocytosis. , 2005, Biochemical and biophysical research communications.
[16] J. Keller,et al. Splice variants of the receptor for advanced glycosylation end products (RAGE) in human brain , 2004, Neuroscience Letters.
[17] J. Enghild,et al. Purification and Characterization of Mouse Soluble Receptor for Advanced Glycation End Products (sRAGE)* , 2004, Journal of Biological Chemistry.
[18] Jeon-Soo Shin,et al. Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. , 2004, Molecular immunology.
[19] P. Rogalla,et al. Tissue-specific expression patterns of the RAGE receptor and its soluble forms--a result of regulated alternative splicing? , 2003, Biochimica et biophysica acta.
[20] G. Taraboletti,et al. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. , 2003, Cancer research.
[21] Ann Marie Schmidt,et al. RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain , 2003, Nature Medicine.
[22] S. Takasawa,et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. , 2003, The Biochemical journal.
[23] J. Arribas,et al. Protein ectodomain shedding. , 2002, Chemical reviews.
[24] Pedro Romero,et al. Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity , 2002, Oncogene.
[25] A. Schmidt,et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease , 2002, Cellular and Molecular Life Sciences CMLS.
[26] L. Matrisian,et al. Matrix metalloproteinases: they're not just for matrix anymore! , 2001, Current opinion in cell biology.
[27] T. Kislinger,et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. , 2001, The American journal of pathology.
[28] G. Struhl,et al. Requirements for presenilin-dependent cleavage of notch and other transmembrane proteins. , 2000, Molecular cell.
[29] T. Kislinger,et al. Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases , 2000, Nature.
[30] P. Malherbe,et al. cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein. , 1999, Brain research. Molecular brain research.
[31] N. Hooper,et al. Cleavage of Alzheimer's amyloid precursor protein by alpha-secretase occurs at the surface of neuronal cells. , 1999, Biochemistry.
[32] M. Racchi,et al. Activity of α‐Secretase as the Common Final Effector of Protein Kinase C‐Dependent and ‐Independent Modulation of Amyloid Precursor Protein Metabolism , 1999, Journal of neurochemistry.
[33] I. Stamenkovic,et al. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. , 1999, Genes & development.
[34] A. Schmidt,et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts , 1998, Nature Medicine.
[35] B. Zlokovic,et al. Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. , 1998, The Journal of clinical investigation.
[36] A. Schmidt,et al. Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. , 1997, Molecular pharmacology.
[37] X. Chen,et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease , 1996, Nature.
[38] K. O. Elliston,et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. , 1992, The Journal of biological chemistry.
[39] A. Eisen,et al. Human skin fibroblast procollagenase: mechanisms of activation by organomercurials and trypsin. , 1983, Biochemistry.